

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Aroa Biosurgery Limited</b>
<b>ARBN</b>	<b>638 867 473</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Brian Ward
<b>Date of last notice</b>	22 August 2024

**Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect														
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A														
<b>Date of change</b>	16 June 2025														
<b>No. of securities held prior to change</b>	<p><b>Indirect</b></p> <p><u>Mr Brian Ward &amp; Mrs Tracey Ward &lt;Arawai No 2 A/C&gt;</u></p> <table style="width: 100%; border: none;"> <tr> <td style="width: 20%;">33,125,800</td> <td>Fully Paid Ordinary Shares</td> </tr> <tr> <td>3,132,525</td> <td>Options exercisable at \$0.75 expiring 23 July 2025</td> </tr> <tr> <td>591,768</td> <td>Options exercisable at \$Nil expiring 13 November 2027*</td> </tr> <tr> <td>649,695</td> <td>Options exercisable at \$1.165 expiring on 13 November 2027</td> </tr> <tr> <td>254,972</td> <td>Options exercisable at \$1.165 expiring 29 February 2028</td> </tr> <tr> <td>453,206</td> <td>Options exercisable at \$Nil expiring 29 February 2028</td> </tr> <tr> <td>961,255</td> <td>Performance Rights expiring 1 August 2027</td> </tr> </table> <p><small>*625,842 Options exercisable at \$Nil exp 13 Nov 2027 were lapsed in June 2024.</small></p>	33,125,800	Fully Paid Ordinary Shares	3,132,525	Options exercisable at \$0.75 expiring 23 July 2025	591,768	Options exercisable at \$Nil expiring 13 November 2027*	649,695	Options exercisable at \$1.165 expiring on 13 November 2027	254,972	Options exercisable at \$1.165 expiring 29 February 2028	453,206	Options exercisable at \$Nil expiring 29 February 2028	961,255	Performance Rights expiring 1 August 2027
33,125,800	Fully Paid Ordinary Shares														
3,132,525	Options exercisable at \$0.75 expiring 23 July 2025														
591,768	Options exercisable at \$Nil expiring 13 November 2027*														
649,695	Options exercisable at \$1.165 expiring on 13 November 2027														
254,972	Options exercisable at \$1.165 expiring 29 February 2028														
453,206	Options exercisable at \$Nil expiring 29 February 2028														
961,255	Performance Rights expiring 1 August 2027														

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Class</b>	Unlisted options												
<b>Number acquired</b>	Nil												
<b>Number disposed</b>	591,768 Options exercisable at \$Nil expiring 13 November 2027												
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil												
<b>No. of securities held after change</b>	<p><b>Indirect</b>  <u>Mr Brian Ward &amp; Mrs Tracey Ward &lt;Arawai No 2 A/C&gt;</u></p> <table> <tr> <td>33,125,800</td> <td>Fully Paid Ordinary Shares</td> </tr> <tr> <td>3,132,525</td> <td>Options exercisable at \$0.75 expiring 23 July 2025</td> </tr> <tr> <td>649,695</td> <td>Options exercisable at \$1.165 expiring on 13 November 2027</td> </tr> <tr> <td>254,972</td> <td>Options exercisable at \$1.165 expiring 29 February 2028</td> </tr> <tr> <td>453,206</td> <td>Options exercisable at \$Nil expiring 29 February 2028</td> </tr> <tr> <td>961,255</td> <td>Performance Rights expiring 1 August 2027</td> </tr> </table>	33,125,800	Fully Paid Ordinary Shares	3,132,525	Options exercisable at \$0.75 expiring 23 July 2025	649,695	Options exercisable at \$1.165 expiring on 13 November 2027	254,972	Options exercisable at \$1.165 expiring 29 February 2028	453,206	Options exercisable at \$Nil expiring 29 February 2028	961,255	Performance Rights expiring 1 August 2027
33,125,800	Fully Paid Ordinary Shares												
3,132,525	Options exercisable at \$0.75 expiring 23 July 2025												
649,695	Options exercisable at \$1.165 expiring on 13 November 2027												
254,972	Options exercisable at \$1.165 expiring 29 February 2028												
453,206	Options exercisable at \$Nil expiring 29 February 2028												
961,255	Performance Rights expiring 1 August 2027												
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Lapse due to vesting conditions not being met.												

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	-
<b>Nature of interest</b>	-
<b>Name of registered holder (if issued securities)</b>	-
<b>Date of change</b>	-
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	-
<b>Interest acquired</b>	-
<b>Interest disposed</b>	-
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	-

+ See chapter 19 for defined terms.

For personal use only

<b>Interest after change</b>	-
------------------------------	---

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

For personal use only

---

+ See chapter 19 for defined terms.